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Abstract
Background: Renal oncocytoma, a benign tumour of the kidney, may pose a differential diagnostic
problem due to overlapping phenotype with chromophobe renal cell carcinoma or other types of
renal cell tumours. Therefore, identification of molecular markers would be of great value for
molecular diagnostics of this tumour type.
Methods: In the current study we applied various techniques, including Affymetrix microarray
hybridization and semiquantitative RT-PCR, to identify genes expressed differentially in renal
oncocytomas. Subsequently, we used RACE and Northern blot hybridization to characterize the
potential candidates for molecular diagnosis.
Results: We have identified new isoform of DLG2 gene, which contains 3'-end exons of the known
DLG2 gene along with the hypothetical gene FLJ37266. The new isoform is specifically upregulated
in renal oncocytoma, whereas the known DLG2 gene is downregulated in this type of kidney
tumour.
Conclusion: The new isoform of DLG2 is the promising candidate gene for molecular differential
diagnostics of renal oncocytoma.
Background
Renal oncocytoma (RO) is a benign tumour of the kidney
accounting for approximately 5% of renal cell tumours. A
typical RO shows a nested or acinar growth of polygonal
cells with central small nuclei and abundant eosinophilic
granular cytoplasm when stained with H&E. However, RO
as well as the malignant chromophobe renal cell carci-
noma (chRCC) may display tubulary, cystic or papillary
growth pattern and the cellular characteristics also may
vary from small cells with scanty cytoplasma through
large eosinophilic granular to "clear" pale cells even
within the same tumour. Therefore, the differential diag-
nosis between the benign RO and some chRCC based
exclusively on the cellular characteristics can be difficult.
Positive staining with Hale's colloidal iron stain and the
presence of cytoplasmic vesicles are considered to be diag-
nostic features for, but it is not limited to chRCCs [1-3].
An overlapping cytological and growth pattern may also
be seen in other malignant renal cell tumours such as con-
ventional RCC (cRCC) and papillary RCC (pRCC).
Previously, we have worked out a novel classification and
differential diagnostic system based on the specific genetic
changes occurring in conventional, chromophobe and
papillary RCCs [4,5]. ROs are characterised either by loss
of chromosomes 1 and 14 and the Y-chromosome or
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translocation between chromosome 11q13 and another
chromosomes or by random genetic changes [6,7]. The
lack of genetic changes specific for other types of renal cell
tumours such as chRCC, pRCC and cRCC may indicate
the diagnosis of RO [5,6,8]. Different molecular tech-
niques such as microsatellite allelotyping and matrix
CGH can be used to detect tumour type specific genetic
alterations which require specific equipments and per-
sonal experienced in these techniques [5,9]. Several
immunhistochemical markers such as CD63, MOC31,
CD10, CDH16, KIT and RCC have been proposed to diag-
nose RO but none of them have been improved [10-13].
In course of a project of gene expression profiling in dif-
ferent types of renal tumours with Affymetrix microarray
hybridization and semiquantitative RT-PCR we have iden-
tified a novel isoform of DLG2 gene upregulated exclu-
sively in RO.
Methods
Tissue samples and RNA isolation
Tissue samples were collected from patients underwent
tumour nephrectomy. A piece of tumour and correspond-
ing normal kidney were snap-frozen immediately after
nephrectomy in liquid nitrogen and stored at -80°C. The
remaining tissue was fixed in 4% buffered formaldehyde
for histological report. Histological diagnosis of tumours
was established according to the Heidelberg Classification
of Renal Cell Tumours [14]. Total RNA was prepared
using modified method of Chomczynski & Sacchi [15].
The concentration and the integrity of RNAs were deter-
mined by spectrophotometry and denaturing agarose gel
electrophoresis. The absence of DNA contamination in
RNA samples was confirmed by PCR of GAPDH with
primers specific to genomic DNA. The collection and use
of all tissue samples for this study were approved by the
Ethics Committee of the University of Heidelberg.
Affymetrix GeneChip Array
We used the Affymetrix Human Genome U133 A and B
GeneChip sets [16] to establish the gene expression in
normal kidney tissues and distinct types of renal cell
tumours. In this experiment we have pooled 3–5 RNAs
each from normal healthy fetal and adult kidneys, Wilms'
tumours, conventional, chromophobe and papillary
RCCs and ROs. The cRNA synthesis, hybridisation onto
Affymetrix Human Genome U133 GeneChip and primary
statistical analysis were performed by the Affymetrix
Screening Service at the German Resource Center for
Genome Research (RZPD). The selection of genes
expressed differentially in ROs (and other types of
tumours) was performed using quantitative and qualita-
tive measures such as signal log ratio, presence/absence
and increase/decrease calls provided with Affymetrix
Microarray Suit software (MAS.1). Genes showing a signal
log ratio over 2 in ROs and under 0 in all other samples
with corresponding detection and change call, i.e. specifi-
cally upregulated in ROs and down regulated in all other
type of tissues were selected for quantitative RT-PCR.
Semiquantitative RT-PCR
The results of microarray analysis were validated with RT-
PCR on a panel of 40 cDNA samples representing 8 indi-
vidual cases of each type of renal cancer, e.g. RO, chRCC,
cRCC and pRCC as well as normal adult kidney. One
microgram of total RNA was used for reverse transcription
(Invitrogen, Superscript II kit), cDNA was denatured and
diluted to 70 μl, 4 μl of this were used for PCR. The reac-
tions were performed using Platinum Sybr Green qPCR
UDG Supermix (Invitrogen) in a total volume of 15 μl.
Detection of PCR product amplification was made by
DNA Engine Opticon system (MJ Research). PCR specifi-
city was controlled by melting curve analysis and agarose
gel electrophoresis. Semi-quantification was performed
with Opticon Monitor software (MJ Research). Expression
of GAPDH and β-actin genes was used for the normaliza-
tion of amplification signals in different samples. The
evaluation of the results was done with statistical analysis
tools of MS Excel.
Rapid amplification of cDNA ends (RACE) and sequencing
SMART RACE cDNA amplification kit (BD Biosciences)
was used to perform 3'- and 5'-RACE of FLJ37266 gene.
RACE-ready cDNA was synthesized according to the man-
ufacturer's instructions. RACE PCR was performed with
gene-specific primers that were used for RT-PCR of
FLJ37266 (Table 1, primers Affy_FLJ37266-F and -R).
RACE products were excised form the agarose gel, puri-
fied, and cloned with TOPO TA Cloning kit (BD Bio-
sciences). Clone inserts were sequenced with LiCor 4200
DNA sequencer using ThermoSequenase Primer Cycle kit
(Amersham Biosciences) with IR700- and IR800-labelled
primers (Table 1). Long distance (LD) exon-specific PCR
was performed using the Advantage Polymerase mix (BD
Biosciences). The list of primers used in the current work
is presented in Table 1.
Northern blot hybridization
Total RNA from normal and tumour tissues (10 μg) was
size-fractionated in 1% denaturing agarose gel and trans-
ferred to membrane (N-Hybond, Amersham Biosciences)
by capillary blotting. PCR probe labeling with DIG-
11dUTP, hybridization, and NBT/BCIP chromogenic sig-
nal detection were carried out according to the manufac-
turer's instructions (DIG Northern starter kit; Roche
Diagnostics, Mannheim, Germany). The labeled probe
was synthesized with the primers complementary to the
genomic region between FLJ37266 and DLG2 genes
(primers intergene_spec-F and intergene_spec-R in Table
1). DIG-labeled RNA Molecular Weight Marker II 1.6–
6.95 kb (Roche Diagnostics) was used to estimate the sizeBMC Cancer 2006, 6:106 http://www.biomedcentral.com/1471-2407/6/106
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of the bands by logarithmic relationship between molec-
ular weight and distance migrated.
Results
Differential expression of FLJ37266 and DLG2 genes in RO
The expression profiling with Affymetrix GeneChip array
revealed a high number of genes expressed in both ROs
and chRCCs (data not shown), but only few genes
expressed exclusively in RO. Among them, FLJ37266 and
DLG2 were most strikingly up-regulated in RO (Log2
ratios 8.1 and 7.8 in comparison to normal kidney,
respectively). Both genes are represented by single target
sequences in Affymetrix HG U133 set: FLJ37266 target
sequence (probe ID: 228973_at) is located at 3'-UTR of
FLJ37266 gene, and the target sequence for DLG2 gene
(probe ID: 206253_at) covers four 3'-terminal exons of
this gene (Fig. 1). Semiquantitative RT-PCR of FLJ37266
and DLG2 gene with the primers complementary to the
target sequences (Affy_DLG2 and Affy_FLJ37266 primer
pairs, Table 1) confirmed the results of microarray hybrid-
ization (Fig. 2).
Single mRNA transcript of FLJ37266 and DLG2 genes
According to Ensembl genome database, DLG2 and
FLJ37266 genes are located at the "minus" strand of chro-
mosome 11q14.1 region only less than 1.5 kb to each
other. The PCR was performed from RO cDNA as a tem-
plate with forward primer specific to DLG2 gene and
reverse primer specific to FLJ37266 gene (Affy_DLG2-F
and Affy_FLJ37266-R, Table 1.) in one reaction. The
amplification product of ~4.7 Kb suggests a single mRNA
transcript for FLJ37266 and DLG2 genes.
Rapid amplification of cDNA ends was performed for
FLJ37266 gene. After cloning and sequencing of the RACE
PCR products, two variants of 5'-end and two variants of
3'-end of FLJ37266 were found. The sequences are depos-
ited at dbEST database under the Accession Nrs.
Table 1: Sequences of oligonucleotide primers
PCR and sequencing primers
Name Sequence 5'->3'
RT-PCR DLG2_spec1-F GATGACCCTGGCATATTTATTACGA
DLG2_spec1-R ACGATAGACCCTGCTTCCTTCA
DLG2_spec2-F TGGGGAACCAACACATTCCT
DLG2_spec2-R TTGCTACTGCCTCTTCGTGTG
Intergene_spec-F GGCCAAAATGCTAAATGGTCCT
Intergene_spec-R CCTCACTTACCTCCCTTCCACA
Affy_DLG2-F GCTCTATCCCATTGCCATCTT
Affy_DLG2-R CGTTGTCAGAGGCGCAGTAT
Affy_FLJ37266-F TGCCAGATCGTGTAACTGGTG
Affy_FLJ37266-R TAGCCAAGAAATCCCGCAAA
RT-PCR controls GAPDH-F GGAAGGTGAAGGTCGGAGTCAAC
GAPDH-R CCACTTGATTTTGGAGGGATCTCG
β-actin-F ATGGATGATGATATCGCCGCGC
β-actin-R TGATGGTGGGCATGGGTCAGAA
Sequencing Amp_F CGTCTCTAACAGAGGAACAAGCCAAG
Amp_R GGAGTGTAAGCTGTGCAGTGTCTC
DLG2_3'-F_2_ IRD800 GAAGCCATGAAGGAAACAGAGG
DLG2_3'-F_IRD700 TTGATTGCCTATTTTGCCATTT
DLG2_5'-F_ IRD700 ACCAGCTTTCGCTATGCAAC
FLJ37266-F_IRD800 TGTTGATGTCTCTATGGCTCCA
FLJ37266-R_IRD700 TGGAGCCATAGAGACATCAACA
LD-PCR FLJ37266_universal-R CAATTCTGTGGGAGGAGAGCAA
DLG_exon22-F GGTGACGACGGTTATGGAACAA
DLG_exon21-F ACAAGGAGCAGAGTGAGCAGGA
DLG_exon20-F GTGCCCGATTGAAGACAGTGAA
DLG_exon19-F ACGACAAGAGCAAGGACAGTGG
DLG_exon18-F CCATGACCTACGAGAGCAGATGA
DLG_exon17-F GGCTGGACAGACAGTGACGATT
DLG_exon16-F GTGTCCTTCATTCTGGCTGGTG
DLG_exon15-F ACATAGCACCGCAACTCGTCAGBMC Cancer 2006, 6:106 http://www.biomedcentral.com/1471-2407/6/106
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CX734843-CX734846. The alignment of the RACE
sequences with genomic DNA and known mRNA
sequences was performed using the BLAT tool [17]. The
schematic representation of the alignment is given at Fig-
ure 1. The 3'-RACE variants of FLJ37266 gene are differed
only with the length of the 3'-UTR whereas the 5'-RACE
isoforms are differed by the termination at the exon 21 or
22 at the 5'-end. These alternative exons are present in
homologous DLG2 mRNAs as well. The most prominent
feature of 5'-RACE isoforms is that they contain the
sequence complementary to the genomic DNA between
the FLJ37266 and DLG2 genes. This implies that, the
spliced mRNA transcript combining the whole FLJ37266
gene, intragenic region, and 3'-part of DLG2 gene is
expressed in RO.
The expression level of the 5'- RACE isoforms was studied
by long-distance (LD) RT-PCR with the forward primers
specific to the DLG2 exons 15–22 and the reverse primer
specific to the FLJ37266 gene (LD primers, Table 1). LD
RT-PCR (Fig. 3) showed that the most abundant variant of
5'-end of FLJ37266-DLG2 transcript corresponds to the
RACE isoform A as it was shown in Figure 1. As revealed
by LD PCR, besides the two 5'-RACE isoforms, some
longer variants of FLJ37266-DLG2 transcript that contain
additional exons at the 5'-end of DLG2 gene are also
expressed at low level. Probably, due to their low abun-
dance they were not detected among the cloned RACE
products. In case of the 3'-RACE, two isoforms were
amplified with quite similar efficiency, which points to
their equal abundance.
Schematic alignment of DLG2 gene isoforms, their genomic position, and localization of RT-PCR primers Figure 1
Schematic alignment of DLG2 gene isoforms, their genomic position, and localization of RT-PCR primers.BMC Cancer 2006, 6:106 http://www.biomedcentral.com/1471-2407/6/106
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The size of FLJ37266-DLG2 transcript was also estimated by Northern blot hybridization (Fig. 4). The calculated
length of the transcript varies from 5.4 to 5.7 Kb, which
roughly corresponds to the cumulative size of 3'- and 5'-
RACE sequences. The part of the FLJ37266 -DLG2 tran-
script, containing the whole FLJ37266 gene, intergene
region, 3'-UTR and two 3'-terminal exons of DLG2 gene
was amplified using the primers Amp_F and Amp_R
(Table 1) from three RO and counterpart normal kidney
cDNAs, then cloned, and sequenced (dbEST Accession
Nrs.: CX727314-CX727319). The accurate examination of
the amplicon sequence revealed no nucleotide differences
in comparison to cDNA sequences of FLJ37266 and DLG2
genes. The part of the amplicon, corresponding to the
intergene region is completely identical to the genomic
DNA, and has multiple stop codons. Thus, the FLJ37266-
DLG2 mRNA transcript does not contain uninterrupted
Exon-specific LD PCR of the new DLG2 gene isoform Figure 3
Exon-specific LD PCR of the new DLG2 gene iso-
form. M – molecular marker; exon-specific PCR products 
for the exons 22–15 as it was shown in Fig. 1; C – negative 
control.
Quantitative RT-PCR of Affymetrix target sequences for FLJ37266 (228973_at) and DLG2 (206253_at) genes in renal tumours Figure 2
Quantitative RT-PCR of Affymetrix target sequences for FLJ37266 (228973_at) and DLG2 (206253_at) genes 
in renal tumours. The diagram shows the averaged level of expression as detected in 8 individual ROs, chRCCs, cRCCs, 
pRCCs and normal renal tissues (N). Both genes are significantly upregulated in ROs in comparison to other types of tumours 
and normal kidney samples (p < 0.05, Student's t-test).
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ORF. The longest ORF was found at the 5'-part of the tran-
script and corresponds to the coding region of DLG2 gene.
Differential expression of FLJ37266-DLG2 transcript and 
DLG2 gene
Microarray hybridization and RT-PCR with the primers
specific to the Affymetrix target sequences corroborated
that FLJ37266 and DLG2 genes are both highly up-regu-
lated in RO. However, the discrimination of the new and
the known DLG2 isoforms was impossible because they
share the same Affymetrix DLG2 target sequence. There-
fore, isoform-specific primers were designed. The primers
specific to the new FLJ37266-DLG2 transcript were com-
plementary to the intergene region (primers
Intergene_spec-F and -R, Table 1). Two primer pairs spe-
cific to the known DLG2 isoform were designed for the
exons present only in this isoform (exons 8 and 9 –
DLG2_spec1 primers and exons 10 and 11 – DLG2_spec2
primers, Table 1). As shown in Figure 5, the opposite pat-
tern of expression change in RO was observed for the dif-
ferent DLG2 isoforms. FLJ37266-DLG2 transcript is
significantly up-regulated in RO in comparison to the nor-
mal kidney and other tumours. The conventional isoform
of DLG2 gene is down-regulated in RO only, whereas the
difference between the normal kidney and the carcinomas
is statistically non-significant.
Discussion
Although the global gene expression of over 200 renal cell
tumours has already been studied, only 6 renal oncocyto-
mas were included in these series [18-20]. The array anal-
yses revealed expression profiles in distinct types of
tumours, such as cRCCs, pRCCs, chRCCs but no specific
expression for RO has been reported. We found that the
whole FLJ37266 gene together with the 3'-end of DLG2
gene and the genomic region between them are tran-
scribed as a single spliced mRNA in renal tissues. During
preparation of the manuscript, mRNA sequence
CR933674 with similar structure was announced at
GeneBank database. We suggest that FLJ37266 gene is a
part of a new isoform of DLG2 gene rather than a separate
gene.
DLG2 belongs to a family of membrane associated guan-
ylate kinases (MAGUKs). MAGUKs are thought to be scaf-
folding molecules playing the central role in establishing
and maintaining the cell polarity in both epithelial cells
and neurons. DLG2 shares the typical structure of
MAGUK proteins including guanilate kinase (GUK), Src
homology 3 (SH3), and three PDZ domains [21,22]. The
longest ORF found in the new DLG2 isoform encodes
GUK and SH3 domains, but not the PDZ domains located
at the N-terminus.
The up-regulation of the novel DLG2 isoform was con-
firmed by different methods including microarray hybrid-
ization, RT-PCR, and Northern blot hybridization. The
specificity of differential expression allows to consider
this DLG2 isoform as a potential molecular marker for the
diagnosis of RO. Especially valuable point is the very low
expression of the new isoform not only in normal kidney,
but also in other types of renal tumour, including chRCC.
On the other hand, the results of RT-PCR indicate the
expression of the known isoform of DLG2 in all other
types of renal cell cancer whereas RO shows a low expres-
sion level.
Conclusion
Although the functional role of the new DLG2 isoform in
ROs is not yet known, it may be a good candidate for
molecular differential diagnosis of RO. It is highly
expressed in RO and show a low expression level in other
types of renal cell tumours and normal kidney tissues
whereas the DLG2 shows an opposite expression pattern.
The significance of the differential expression in the rou-
tine pathology will be improved after arising isoform spe-
cific antibodies and immunohistochemical analysis of a
large series of tumours.
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Quantitative RT-PCR of the novel and known isoforms of DLG2 gene in renal tumours Figure 5
Quantitative RT-PCR of the novel and known isoforms of DLG2 gene in renal tumours. The diagramms show the 
averaged level of expression of the two DLG2 isoforms in 8 individual ROs, chRCCs, cRCCs, pRCCs and normal renal tissues 
(N). The new isoform of DLG2 is significantly upregulated in ROs in comparison to normal kidney and other types of tumours 
(p < 0.001, Student's test). The known isoform of DLG2 was significantly downregulated in ROs in comparison to normal kid-
ney samples (p < 0.005, Student's test) but not against other types of tumours.
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